We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Lipid Levels from Non-Fasting Patients Deemed Suitable for Assessing CVD Risk

By LabMedica International staff writers
Posted on 04 Jun 2019
Results published in a recent paper suggested strongly that lipid levels measured in blood samples from non-fasting patients were accurate and predicative of future cardiovascular risk.

A team of investigators from Brigham and Women's Hospital (Boston, MA, USA), Harvard Medical School (Boston, MA, USA), and Imperial College London (United Kingdom) sought to determine how non-fasting lipid levels compared with fasting lipid levels measured in the same individuals for assessing cardiovascular risk, and what was their association with incident cardiovascular events.

To this end they performed a secondary analysis of the results of a randomized clinical trial that included 8270 of 10,305 participants from the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA) with non-fasting and fasting lipid levels measured four weeks apart (including 6855 participants with no prior vascular disease). More...
Data were collected from February 1, 1998, to December 31, 2002, and analyzed from February 1, 2016, to November 30, 2018.

Analysis of the results revealed that among the 8270 participants (82.1% male; mean age, 63.4 years), non-fasting samples had modestly higher triglyceride levels and similar cholesterol levels compared to fasting samples. Associations of non-fasting lipid levels with coronary events were similar to those for fasting lipid levels.

"We hope this study will be the final nail in the coffin, providing strong evidence that, within the same person, fasting or not before a lipid level test does not matter for predicting cardiovascular risk," said senior author Dr. Samia Mora, director of the center for lipid metabolomics at Brigham and Women's Hospital. "This should reassure health care providers and patients that it does not make a difference if you fast or do not fast if the goal is to predict your cardiovascular risk."

"We spend most of our lives in a non-fasting state. And for some patients, especially those who are elderly or have diabetes, it can be risky to fast before lipid testing," said Dr. Mora. "Health care providers held back because of concerns of variability within individuals, but the data here is so convincing. It should allow people to feel more comfortable with non-fasting lipid testing for cardiovascular risk assessment, including when taking a statin."

The paper was published in the May 28, 2019, online edition of the journal JAMA Internal Medicine.

Related Links:
Brigham and Women's Hospital
Harvard Medical School
Imperial College London

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.